Foreign protein production in transgenic plants has been successful, from t
he generation of transgenic plant lines to the marketing of purified protei
ns. Antigenic proteins from disease organisms, monoclonal antibodies raised
against antigens of disease organisms, and proteins with industrial proces
s applications have been produced and tested. For vaccines, clinical trials
in humans and feeding trials in animals are in progress to demonstrate the
ir efficacy. For industrial proteins, high expression and downstream proces
sing efficiency are key concerns, with application and test market trials i
n progress.